A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroid
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms AD Up
- Sponsors AbbVie
- 14 Nov 2018 Planned End Date changed from 16 May 2022 to 6 May 2022.
- 05 Sep 2018 Planned End Date changed from 9 May 2022 to 16 May 2022.
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.